<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypertension associated with erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypertension associated with erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypertension associated with erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wajeh Y Qunibi, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypertension is a common adverse effect of erythropoietin treatment among patients with chronic kidney disease (CKD) [<a href="#rid1">1,2</a>]. Hypertension has also been described following the use of other erythropoiesis-stimulating agents (ESAs) in patients with CKD [<a href="#rid3">3</a>]. Among these patients, hypertension may develop de novo or may worsen after introducing ESAs. However, since hypertension in patients with CKD is often due to other factors (eg, volume overload), erythropoietin-related hypertension is often overlooked.</p><p>This topic reviews hypertension related to erythropoietin among patients with CKD. Other issues related to erythropoietin among patients with CKD, including hemoglobin (Hb) targets, are addressed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1935.html" rel="external">"Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H10616402"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Overall, approximately 20 to 30 percent of patients who receive erythropoietin intravenously for the anemia of CKD develop an elevation in diastolic pressure of 10 mmHg or more [<a href="#rid1">1,4</a>]. A phase-III trial involving 251 patients on hemodialysis found that 35 percent of patients developed an increase in their diastolic blood pressure (BP) of at least 10 mmHg or required an increase in their antihypertensive agents after three months of ESA therapy. Moreover, 44 percent of patients who were not hypertensive at baseline also had an increase in diastolic BP of at least 10 mmHg, and one-third of them were started on antihypertensive therapy [<a href="#rid5">5</a>].</p><p>Much of the evidence that ESAs contribute to hypertension in patients with CKD was derived from a series of meta-analyses [<a href="#rid1">1,2</a>]. As an example, in one meta-analysis that included six randomized trials comparing erythropoietin versus placebo or no erythropoietin (n = 387 patients), patients who did not receive erythropoietin had a lower risk of hypertension (relative risk [RR] 0.50, 95% CI 0.33-0.76).</p><p>Another meta-analysis from the Cochrane Collaboration that included four controlled trials in patients with nondialysis CKD showed a 26 percent higher risk of hypertension in erythropoietin-treated patients compared with no erythropoietin or placebo, but the effect was not statistically significant [<a href="#rid6">6</a>].</p><p>A subsequent meta-analysis of the effects of ESA treatment on hypertension, compared with placebo or no treatment, was provided from 24 studies in 9930 participants [<a href="#rid3">3</a>]. The meta-analysis showed that all ESAs increased the odds of hypertension compared with placebo (<a class="drug drug_general" data-topicid="9410" href="/z/d/drug information/9410.html" rel="external">epoetin alfa</a> odds ratios [OR] 2.31, 95% CI 1.27-4.23; epoetin beta OR 2.57, 95% CI 1.23-5.39; <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">darbepoetin alfa</a> OR 1.83, 95% CI 1.05-3.21; <a class="drug drug_general" data-topicid="101636" href="/z/d/drug information/101636.html" rel="external">methoxy polyethylene glycol-epoetin beta</a> OR 1.96, 95% CI 0.98-3.92), while the effect of biosimilar ESAs on developing hypertension was less certain [<a href="#rid3">3</a>].</p><p>Hypertension was much more common in the early years of ESA use. At that time, the rise in hemoglobin (Hb) was more rapid because of administration of significantly larger doses of ESAs compared with the doses used in current practice [<a href="#rid7">7</a>]. A subsequent meta-analysis has shown a decrease in the hypertensive effects of ESA therapy over time [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H2228032896"><span class="h2">Risk factors for ESA-associated hypertension</span><span class="headingEndMark"> — </span>Putative risk factors for ESA-associated hypertension include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous administration (versus subcutaneous)</p><p class="bulletIndent1"><span class="glyph">●</span>Hemodialysis versus continuous ambulatory peritoneal dialysis (CAPD) or no dialysis</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Higher Hb target</p><p class="bulletIndent1"><span class="glyph">●</span>Higher ESA dose</p><p></p><p>An early report suggested that the BP may be less likely to rise after subcutaneous administration, possibly related to a slower increase in Hb concentration [<a href="#rid9">9</a>]. The magnitude of the BP increase is greater in hemodialysis than in predialysis or CAPD patients [<a href="#rid2">2,10,11</a>]. Hypertension following erythropoietin may be more frequent in patients with a personal or family history of hypertension [<a href="#rid12">12</a>].</p><p>The risk of hypertension is increased by targeting higher Hb concentrations. This was suggested by the CREATE study, which reported a greater than 50 percent increase in risk for developing hypertension in patients targeted to a Hb of 13 to 15 g/dL compared with those targeted to 10.5 to 11.5 g/dL [<a href="#rid13">13</a>]. A meta-analysis comprising nine studies, including the CREATE study, also reported a higher risk of poorly controlled BP in patients targeted to higher Hb levels [<a href="#rid14">14</a>]. A meta-analysis that included 27 studies concluded that targeting higher Hb levels with ESA therapy worsens hypertension [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis"</a>.)</p><p>Two factors were thought to be associated with hypertension: the high doses of erythropoietin administered and the rapid rate of increase in Hb concentration. A high ESA dose was associated with increased risk of hypertension in a meta-regression analysis that included 31 randomized, controlled trials [<a href="#rid15">15</a>]. However, the association between ESA dose and hypertension was not significant after adjusting for target Hb concentration [<a href="#rid15">15</a>].</p><p>Antiplatelet agents may reduce the risk of erythropoietin-induced hypertension. In one study, for example, the incidence of hypertension after erythropoietin was only 6 percent in patients treated with one of these drugs as compared with 56 percent in those not receiving antiplatelet therapy [<a href="#rid16">16</a>]. Why this might occur is not clear.</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The underlying mechanisms that increase the blood pressure (BP) level in ESA-treated patients remain poorly defined [<a href="#rid17">17</a>]. The effect seems to be independent of ESA effect on red blood cell volume and viscosity. It seems that there are separate epitopes on the erythropoietin protein: One epitope is involved in mediating erythropoiesis, and another mediates the effects on BP increase [<a href="#rid18">18</a>]. Pertinent to this is that erythropoietin receptors are expressed on vascular endothelial cells and smooth muscle cells and thus may facilitate a role for erythropoietin in cellular signal transduction pathways that triggers vasoconstriction and an increase in BP [<a href="#rid19">19</a>]. A consistent finding in experimental and clinical studies is increased systemic and renal vasoconstriction after ESA administration. This effect may be mediated, at least in part, by the direct vasoconstrictor action of erythropoietin on renal resistance vessels [<a href="#rid20">20</a>]. However, multiple other factors may also contribute, including [<a href="#rid2">2,5,12,17,20-30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Enhanced vascular alpha adrenergic sensitivity</p><p class="bulletIndent1"><span class="glyph">●</span>Diminished production of nitric oxide</p><p class="bulletIndent1"><span class="glyph">●</span>Reversal of hypoxia-induced vasodilation after correction of anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Marked increase in cytosolic free calcium levels in vascular smooth muscle cells [<a href="#rid31">31</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Increased plasma endothelin levels [<a href="#rid32">32-34</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial remodeling through stimulation of vascular cell growth</p><p class="bulletIndent1"><span class="glyph">●</span>Activation of the renin-angiotensin system</p><p class="bulletIndent1"><span class="glyph">●</span>Elevation of the thromboxane: prostacyclin ratio in vascular tissue</p><p></p><p>Preexisting chronic kidney disease also seems to play a major role in the genesis of erythropoietin-induced hypertension. In animal studies, administration of erythropoietin increased systolic BP in rats with, but not without, subtotal nephrectomy [<a href="#rid35">35,36</a>].</p><p>One study examined the effects of erythropoietin on vascular responsiveness to <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> [<a href="#rid21">21</a>]. Intra-arterial infusions of norepinephrine in anemic patients on hemodialysis caused a decrease in forearm blood flow and an increase in forearm vascular resistance that was significantly less than that found in healthy controls. Repeat studies performed after 6 and 12 weeks of erythropoietin therapy demonstrated that vascular responsiveness to norepinephrine had been restored to values equal to or greater than the control subjects. Mean arterial pressure also significantly increased during erythropoietin therapy. An almost fourfold increase in vasoconstrictor sensitivity to alpha adrenergic stimuli was also evident in the venous circulation of erythropoietin-treated patients on hemodialysis compared with healthy subjects, but vasorelaxation in response to bradykinin was unchanged in both groups [<a href="#rid29">29</a>]. Of note, erythropoietin infusion into hand veins of healthy subjects produced no vasoconstriction.</p><p>High doses of ESA may limit endothelium-derived nitric oxide (NO) production, which contributes to endothelial dysfunction and hypertension [<a href="#rid37">37,38</a>]. Erythropoietin dose-dependently raised asymmetrical dimethylarginine (an endogenous inhibitor of NO synthase) via downregulation of dimethylarginine dimethylaminohydrolase and lowered NO production in cultured endothelial cells [<a href="#rid39">39</a>].</p><p>From a hemodynamic viewpoint, the elevation in BP is consistent with rapid reversal of anemia-induced peripheral vasodilatation with a less than complete reversal of the anemia-induced rise in cardiac output [<a href="#rid40">40</a>]. Why this occurs is not well understood, but impaired myocardial compliance resulting from the cardiac hypertrophy commonly seen in uremia may be an important factor. In older adult patients treated with erythropoietin, the high cardiac output gradually falls over a period of one year and is accompanied by a 25 percent reduction in left ventricular mass [<a href="#rid41">41</a>].</p><p>Endothelin is a very potent vasoconstrictor peptide that may play a role in ESA-induced hypertension [<a href="#rid32">32-34</a>]. In a study of 51 patients on maintenance hemodialysis, 19 had an increase in BP after eight weeks of treatment with erythropoietin. There was an increase in plasma immunoreactive (IR) endothelin concentrations only in the patients with an increase in mean BP greater than 10 mmHg. The increases in plasma IR-endothelin concentrations correlated with the increase in mean BP [<a href="#rid32">32</a>]. However, other studies have not been able to show upregulation of endothelin in human aortic endothelial cells in response to <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">darbepoetin alfa</a> [<a href="#rid42">42</a>].</p><p>Finally, erythropoietin may exert an antinatriuretic effect, likely mediated by angiotensin II, an effect that can contribute to hypertension [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H10616481"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Hypertension may appear as early as two weeks after initiation of ESA treatment, but its onset may be delayed for four months or more. The increase in blood pressure (BP) is usually mild, but hypertensive crisis with encephalopathy has been reported [<a href="#rid44">44</a>]. (See <a class="local">'Hypertensive encephalopathy'</a> below.)</p><p>At the other end of the spectrum, some chronically hypotensive patients on dialysis show an improvement in BP following erythropoietin therapy. However, this does not appear to be associated with a lessening of hemodynamic instability during dialysis [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Hypertensive encephalopathy</span><span class="headingEndMark"> — </span>Hypertensive encephalopathy, sometimes accompanied by seizures, may occur when erythropoietin causes a rapid rise in BP [<a href="#rid46">46</a>]. Hyperperfusion of the cerebral circulation due to a breakdown of cerebral autoregulation may be important in these cases [<a href="#rid12">12</a>]. It is not possible to predict in advance who will develop this complication; as a result, prodromal symptoms (such as persistent headache or visual disturbances) must be looked for, particularly in previously normotensive individuals in the early weeks and months after the institution of erythropoietin therapy.</p><p class="headingAnchor" id="H4"><span class="h1">PREVENTION AND TREATMENT</span><span class="headingEndMark"> — </span>In patients with preexisting severe hypertension, we usually delay the administration of ESAs until the blood pressure (BP) is controlled by antihypertensive medications and volume removal. For patients on dialysis, we try to achieve the estimated dry weight before starting an ESA. Thus, BP must be closely monitored in all patients with CKD before and during initiation of ESAs.</p><p>Therapy of ESA-induced hypertension begins with prevention. The risk of hypertension can be ameliorated by raising the hemoglobin (Hb) <strong>slowly</strong> [<a href="#rid47">47</a>]. If there has been a rapid rise in the Hb levels, the ESA dose should be reduced.</p><p>The risk may also be lessened by aiming for the target Hb levels of 10 to a maximum of 11.5 g/dL, since targeting higher Hb concentrations has been associated with increased risk of ESA-associated hypertension (see <a class="local">'Epidemiology and risk factors'</a> above). Target Hb levels in patients with CKD are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Target hemoglobin value'</a> and  <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Target Hb levels'</a>.)</p><p>The use of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF PHI) may not have the same tendency to cause hypertension. The HIF-mediated transcriptional cascade involves many genes that participate in vasomotor control. The balance between HIF-1 alpha and HIF-2 alpha is critical for the maintenance of systemic arterial pressure and may contribute to a modest BP lowering effect [<a href="#rid48">48</a>]. In a preclinical study, for example, the HIF PHI molidustat resulted in normalization of hypertension in anemic rats with CKD, an effect that was comparable to <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a> [<a href="#rid49">49</a>]. However, in clinical trials, the effect of HIF PHIs on hypertension has been mixed [<a href="#rid50">50-56</a>]. A few of the key trials are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Uncertain role for hypoxia-inducible factor prolyl hydroxylase inhibitors'</a>.) </p><p>Patients who remain hypertensive can be treated with fluid removal (via ultrafiltration during dialysis or, if the patient has only CKD, diuretics) and the administration of antihypertensive agents [<a href="#rid44">44</a>]. Any of the conventional antihypertensive agents can be used to control BP, including angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, calcium channel blockers, and vasodilators (see  <a class="medical medical_review" href="/z/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease", section on 'Treatment of hypertension in chronic kidney disease'</a> and  <a class="medical medical_review" href="/z/d/html/1848.html" rel="external">"Hypertension in patients on dialysis", section on 'Treatment'</a>). The dose of ESAs should be reduced or temporarily discontinued for several weeks in severe cases or when other therapeutic measures are ineffective in controlling BP.</p><p class="headingAnchor" id="H25671830"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Hypertension is a common adverse effect of treatment with erythropoiesis-stimulating agents (ESAs) among patients with chronic kidney disease (CKD). Blood pressure (BP) increases of 10 mmHg or more have been noted in 20 to 30 percent of patients who receive intravenous erythropoietin for the anemia of chronic kidney disease (CKD). Subcutaneous erythropoietin administration is less likely to have this effect. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The mechanisms of erythropoietin-induced hypertension are incompletely understood. However, altered vascular responsiveness to circulating vasoconstrictors and vasodilators combined with impaired myocardial compliance are likely participants. Higher targeted hemoglobin (Hb) levels are also associated with poorer BP control. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and treatment</strong> – Therapy of ESA-induced hypertension begins with prevention. The risk of hypertension can be ameliorated by raising the Hb <strong>slowly</strong>. If there has been a rapid rise in the Hb levels, the ESA dose should be reduced. The risk for hypertension may also be lessened by aiming for target levels for Hb of 10 to 11.5 g/dL. Patients who still remain hypertensive can be treated with fluid removal (via dialysis or, if the patient has only CKD, diuretics) and the administration of antihypertensive agents. The dose of ESA should be reduced or discontinued for several weeks in patients with severe hypertension or when other therapeutic measures are ineffective. (See <a class="local">'Prevention and treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H346556012"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The authors and the editorial staff at UpToDate would like to acknowledge Robert E Cronin, MD, and William Henrich, MD, MACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15:3154.</a></li><li><a class="nounderline abstract_t">Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009; 4:470.</a></li><li><a class="nounderline abstract_t">Palmer SC, Saglimbene V, Mavridis D, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014; 2014:CD010590.</a></li><li><a class="nounderline abstract_t">Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59:538.</a></li><li><a class="nounderline abstract_t">Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111:992.</a></li><li><a class="nounderline abstract_t">Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005; :CD003266.</a></li><li><a class="nounderline abstract_t">Boyle SM, Berns JS. Erythropoietin and resistant hypertension in CKD. Semin Nephrol 2014; 34:540.</a></li><li><a class="nounderline abstract_t">Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153:23.</a></li><li><a class="nounderline abstract_t">Watson AJ, Gimenez LF, Cotton S, et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990; 89:432.</a></li><li><a class="nounderline abstract_t">Nissenson AR, Korbet S, Faber M, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995; 5:1517.</a></li><li class="breakAll">Neeman T, Mats V. FDA statistical review. HFM-570, BLA 97–0006. EPO label extension for pediatric hemodialysis patients. May 23, 1997. www.fda.gov.</li><li><a class="nounderline abstract_t">Ishimitsu T, Tsukada H, Ogawa Y, et al. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med 1993; 94:401.</a></li><li><a class="nounderline abstract_t">Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071.</a></li><li><a class="nounderline abstract_t">Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369:381.</a></li><li><a class="nounderline abstract_t">Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013; 61:44.</a></li><li><a class="nounderline abstract_t">Caravaca F, Pizarro JL, Arrobas M, et al. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 1994; 45:845.</a></li><li><a class="nounderline abstract_t">Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33:821.</a></li><li><a class="nounderline abstract_t">Lee MS, Lee JS, Lee JY. Prevention of erythropoietin-associated hypertension. Hypertension 2007; 50:439.</a></li><li><a class="nounderline abstract_t">Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 2001; 10:633.</a></li><li><a class="nounderline abstract_t">Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39:259.</a></li><li><a class="nounderline abstract_t">Hand MF, Haynes WG, Johnstone HA, et al. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48:806.</a></li><li><a class="nounderline abstract_t">Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18:76.</a></li><li><a class="nounderline abstract_t">Marrero MB, Venema RC, Ma H, et al. Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int 1998; 53:1259.</a></li><li><a class="nounderline abstract_t">Brochu E, Lacasse S, Larivière R, et al. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 1999; 10:1440.</a></li><li><a class="nounderline abstract_t">Miyashita K, Tojo A, Kimura K, et al. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 2004; 27:79.</a></li><li><a class="nounderline abstract_t">Lerche D, Schmidt R, Zoellner K, et al. Rheology in whole blood and in red blood cells under recombinant human erythropoietin therapy. Contrib Nephrol 1989; 76:299.</a></li><li><a class="nounderline abstract_t">Anastassiades E, Howarth D, Howarth J, et al. Influence of blood volume on the blood pressure of predialysis and peritoneal dialysis patients treated with erythropoietin. Nephrol Dial Transplant 1993; 8:621.</a></li><li><a class="nounderline abstract_t">Vaziri ND. Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease? Nat Clin Pract Nephrol 2008; 4:436.</a></li><li><a class="nounderline abstract_t">Abiose AK, Aronow WS, Moreno H Jr, et al. Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin. Am J Ther 2007; 14:427.</a></li><li><a class="nounderline abstract_t">Briet M, Barhoumi T, Mian MO, et al. Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc 2013; 2:e000128.</a></li><li><a class="nounderline abstract_t">Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 1993; 27:1233.</a></li><li><a class="nounderline abstract_t">Takahashi K, Totsune K, Imai Y, et al. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci (Lond) 1993; 84:47.</a></li><li><a class="nounderline abstract_t">Bode-Böger SM, Böger RH, Kuhn M, et al. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996; 50:1255.</a></li><li><a class="nounderline abstract_t">Carlini RG, Dusso AS, Obialo CI, et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43:1010.</a></li><li><a class="nounderline abstract_t">Poux JM, Lartigue M, Chaisemartin RA, et al. Uraemia is necessary for erythropoietin-induced hypertension in rats. Clin Exp Pharmacol Physiol 1995; 22:769.</a></li><li><a class="nounderline abstract_t">Lacasse-M S, Kingma I, Larivière R, et al. Uremia enhances the blood pressure response to erythropoietin. Clin Exp Hypertens 1997; 19:389.</a></li><li><a class="nounderline abstract_t">Vaziri ND, Zhou XJ, Naqvi F, et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 1996; 271:E113.</a></li><li><a class="nounderline abstract_t">Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009; 24:1082.</a></li><li><a class="nounderline abstract_t">Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33:894.</a></li><li><a class="nounderline abstract_t">Mayer G, Hörl WH. Cardiovascular effects of increasing hemoglobin in chronic renal failure. Am J Nephrol 1996; 16:263.</a></li><li><a class="nounderline abstract_t">Martinez-Vea A, Bardají A, García C, et al. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney Dis 1992; 19:353.</a></li><li><a class="nounderline abstract_t">Yang WS, Chang JW, Han NJ, Park SK. Darbepoetin alfa suppresses tumor necrosis factor-α-induced endothelin-1 production through antioxidant action in human aortic endothelial cells: role of sialic acid residues. Free Radic Biol Med 2011; 50:1242.</a></li><li><a class="nounderline abstract_t">Brier ME, Bunke CM, Lathon PV, Aronoff GR. Erythropoietin-induced antinatriuresis mediated by angiotensin II in perfused kidneys. J Am Soc Nephrol 1993; 3:1583.</a></li><li><a class="nounderline abstract_t">Novak BL, Force RW, Mumford BT, Solbrig RM. Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature. Pharmacotherapy 2003; 23:265.</a></li><li><a class="nounderline abstract_t">Onoyama K, Hori K, Osato S, Fujishima M. Haemodynamic effect of recombinant human erythropoietin on hypotensive haemodialysis patients. Nephrol Dial Transplant 1991; 6:562.</a></li><li><a class="nounderline abstract_t">Edmunds ME, Walls J, Tucker B, et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4:1065.</a></li><li><a class="nounderline abstract_t">Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994; 4:1874.</a></li><li><a class="nounderline abstract_t">Yousaf F, Spinowitz B. Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin? Curr Hypertens Rep 2016; 18:23.</a></li><li><a class="nounderline abstract_t">Flamme I, Oehme F, Ellinghaus P, et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One 2014; 9:e111838.</a></li><li><a class="nounderline abstract_t">Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. J Am Soc Nephrol 2021; 32:737.</a></li><li><a class="nounderline abstract_t">Akizawa T, Nangaku M, Yonekawa T, et al. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. Clin J Am Soc Nephrol 2020; 15:1155.</a></li><li><a class="nounderline abstract_t">Chen N, Hao C, Peng X, et al. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. N Engl J Med 2019; 381:1001.</a></li><li><a class="nounderline abstract_t">Haase VH, Chertow GM, Block GA, et al. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant 2019; 34:90.</a></li><li><a class="nounderline abstract_t">Chen N, Hao C, Liu BC, et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. N Engl J Med 2019; 381:1011.</a></li><li><a class="nounderline abstract_t">Zheng Q, Wang Y, Yang H, et al. Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis 2023; 81:434.</a></li><li><a class="nounderline abstract_t">Chen D, Niu Y, Liu F, et al. Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis. Front Pharmacol 2023; 14:1163908.</a></li></ol></div><div id="topicVersionRevision">Topic 1979 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579519" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19218474" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25486075" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14499855" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The cardiovascular effects of erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2688507" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034896" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416663" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Erythropoietin and resistant hypertension in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439566" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220877" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7703390" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Multicenter trial of erythropoietin in patients on peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7703390" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multicenter trial of erythropoietin in patients on peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8475933" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108342" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Normalization of hemoglobin level in patients with chronic kidney disease and anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276778" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22921639" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196287" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10213636" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mechanism of erythropoietin-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548719" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevention of erythropoietin-associated hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496057" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cardiovascular effects of erythropoietin and anemia correction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002640" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7474668" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928084" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effects of erythropoietin on blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573541" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10405199" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15005270" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2684529" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rheology in whole blood and in red blood cells under recombinant human erythropoietin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8396746" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Influence of blood volume on the blood pressure of predialysis and peritoneal dialysis patients treated with erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18542121" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17890929" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23584809" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8252582" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8382133" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8887285" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8510379" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8575115" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Uraemia is necessary for erythropoietin-induced hypertension in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9140703" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Uremia enhances the blood pressure response to erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8760088" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987263" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10082505" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Erythropoietin depresses nitric oxide synthase expression by human endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8739276" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cardiovascular effects of increasing hemoglobin in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1532883" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21334436" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Darbepoetin alfa suppresses tumor necrosis factor-α-induced endothelin-1 production through antioxidant action in human aortic endothelial cells: role of sialic acid residues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507814" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Erythropoietin-induced antinatriuresis mediated by angiotensin II in perfused kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12587817" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1956555" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Haemodynamic effect of recombinant human erythropoietin on hypotensive haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2517327" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Seizures in haemodialysis patients treated with recombinant human erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7919137" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26894597" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25392999" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33568383" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32723804" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31340089" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29672740" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31340116" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36396085" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37292157" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
